Peptide Field Book

Reading settings

Choose a comfortable text size and appearance. Your choices are saved on this device.

Survodutide

Experimental drug for weight loss

Boehringer Ingelheim, BI 456906

Match every finding to its exact substance, formulation, route and study population. A related molecule or approved medicine does not validate a catalog vial.

Human / product-specific records · Unresolved sources · Mechanistic / indirect records
Explore the evidenceWhy people take it
Compare this compoundRead original sources Community reports
Schematic illustration · View structure evidence

Simplified drawing of a chain of 29 amino acids, with its acyl tail

At a glance

Why people take it. And what backs it up.

  1. Lose weight

    Proven in large trials, not approved

    Trial volunteers take it to lose weight; in a large trial, adults with obesity lost about 12–13% over 76 weeks, versus about 5% on placebo.

    Sources (5)

  2. Boost tirzepatide’s weight loss

    People report it, not studied

    Gray-market users add it to tirzepatide as a homemade stand-in for retatrutide, hoping to break a weight-loss stall.

    Sources (3)

Evidence briefing

Sources checked

What the sources support.

Survodutide is an investigational GLP-1/glucagon dual agonist. Phase 2 obesity results showed larger losses among adherent participants; newer phase 3 results report lower treatment-regimen averages at 76 weeks. It is not approved.

Keep in mind

The approximately 19% phase 2 estimate is adherence-based, not the treatment-regimen average.

Identity and research status reviewRead the original sources

The research. What’s been studied.

TapClick a dotted word to see what it means.

  • Human evidence

    Weight loss

    In a obesity trial, treatment-regimen weight loss averaged about 12–13% at 76 weeks, compared with about 5% on placebo. The roughly 19% Phase 2 estimate applied to participants who stayed on planned treatment.

  • Early human studies

    MASH research

    Phase 2 studies reported improvement in some liver-biopsy measures. In the Phase 3 SYNCHRONIZE-MASLD trial (216 adults), 68.5% on survodutide cut liver fat by at least 30% on MRI, versus 28.6% on placebo (84% versus 24% among those who stayed on treatment); biopsy-confirmed MASH benefit still rests on Phase 2.

  • Early human studies

    Two receptor targets

    Survodutide activates and glucagon receptors; the clinical effects and risks are still being studied.

What do these labels mean?
  • Human evidence: approved-drug data or larger human studies, within the populations and uses studied.
  • Early human studies: small, preliminary or limited human studies.
  • Animal & lab studies: animal or laboratory findings that do not establish effects in people.
  • Unverified: a proposed use or claim without verified supporting clinical evidence.
How each claim was reviewed (4)

Reported effects and evidence.

A citation may support, qualify or correct a claim. Read the study scope; a laboratory result is not an established benefit in people. Each review covers a claim as it was first collected; the tiles above show the collection’s current wording.

  1. Human phase 2 and phase 3 RCTs

    Review of “Weight loss”

    Retain phase 2 results with their estimand, and add the newer SYNCHRONIZE-1 trial separately rather than presenting a single universal weight-loss figure.

    Limitations and applicability. Historical 19% estimate is analysis-specific. 2026 phase 3 treatment-regimen estimates were 12.2–13.0% versus 5.4% placebo at 76 weeks.

    Original collected claim and review history

    Original title: Weight loss

    About 19% weight loss at 46 weeks in Phase 2 among people who stayed on the planned dose.

    Original headline statistic: About 19%

    Original label: early. Preserved for traceability; the reviewed wording above qualifies this record.

    Record survodutide:benefit:1 · Annotated 2026-10-01 · Review method

  2. Human phase 2 histology RCT

    Review of “Fatty liver (MASH) improvement”

    The primary analysis found MASH improvement without fibrosis worsening in up to 62% versus 14% with placebo. Preserve 83% only with its exact alternative-analysis source.

    Limitations and applicability. Published primary analysis reported 47%, 62% and 43% across active groups versus 14% placebo. The 83% headline lacks its analysis-set qualifier.

    Original collected claim and review history

    Original title: Fatty liver (MASH) improvement

    Up to 83% of people with MASH improved in a Phase 2 trial.

    Original headline statistic: Up to 83%

    Original label: early. Preserved for traceability; the reviewed wording above qualifies this record.

    Record survodutide:benefit:2 · Annotated 2026-10-01 · Review method

  3. Unknown — no direct primary source verified. Mechanistic interpretation; clinical mechanism unverified

    Review of “Burns more energy”

    Survodutide activates glucagon and GLP-1 receptors. Separate measured liver outcomes from hypotheses about energy expenditure.

    Limitations and applicability. “Pulls fat out” and increased energy expenditure overstate a mechanistic inference.

    Unknown: no direct primary source verified. This does not mean that no research exists.

    Original collected claim and review history

    Original title: Burns more energy

    Its glucagon component raises energy expenditure and pulls fat out of the liver.

    Original label: early. Preserved for traceability; the reviewed wording above qualifies this record.

    Record survodutide:benefit:3 · Annotated 2026-10-01 · Review method

  4. Pharmacology consistent with trial design

    Review of “Appetite control”

    Survodutide includes GLP-1-receptor activity; label appetite suppression as pharmacology rather than a distinct established benefit.

    Limitations and applicability. A GLP-1 mechanism is plausible, but the claim should not masquerade as a separately measured clinical outcome.

    Original collected claim and review history

    Original title: Appetite control

    Its GLP-1 component reduces hunger.

    Original label: early. Preserved for traceability; the reviewed wording above qualifies this record.

    Record survodutide:benefit:4 · Annotated 2026-10-01 · Review method

The research in detail

Evidence category

Human trials, not approved

In the Phase 3 obesity trial, average treatment-regimen weight loss at 76 weeks was about 12–13%, versus about 5% with placebo. The often-cited 19% Phase 2 result was an adherence-based estimate. A Phase 3 liver-fat trial (SYNCHRONIZE-MASLD) reported larger MRI liver-fat reductions than placebo; biopsy-based Phase 3 MASH studies are ongoing. Survodutide is not approved.

Evidence is assessed claim by claim above. Regulatory approval, study design, findings and relevance are separate questions; there is no single evidence score.

Risks and unknowns. What to know first.

Collected cautions follow. These are not an exhaustive or independently validated safety assessment; claim references do not automatically support every caution.

  • Nausea, vomiting and diarrhea were common and led to many dropouts at high doses.
  • Raises heart rate.

What people report

Show all 5 cautionsShow fewer cautions

Read this first: what “research use only” means

Published dosing records. What the trials used.

Historical label and trial records for the named product, route, population and indication. These records are not a personal schedule or a validated regimen for a catalog vial. Source attribution does not establish applicability.

Phase 3 obesity trial

Phase 3 trial (SYNCHRONIZE-1) in adults with obesity, or overweight plus a related condition, without diabetes (New England Journal of Medicine, 2026)

Long-termClinical trial

Source: le Roux et al., New England Journal of Medicine, 2026 (SYNCHRONIZE-1)

After the starting ramp
6 mg
How
Injection under the skin
How often
Once a week
How long
76 weeks in the trial

Limit. Highest dose tested: 6.0 mg once a week.

  • The dose was raised in steps at the start, and the ramp could be stretched out if stomach or bowel side effects occurred.
  • Another group had its dose raised to 3.6 mg.
  • After reaching 3.6 mg, and up to week 32, a dose increase could be delayed or the dose cut by one step for 2–4 weeks.
  • Stomach or bowel side effects occurred in 89.7% of the 6.0 mg group and 47.9% of the placebo group.

Phase 3 liver trial

Phase 3 trial (SYNCHRONIZE-MASLD) in adults with obesity (or overweight plus an obesity-related condition) and fatty liver disease with signs of liver inflammation or scarring (Nature Medicine, 2026)

Long-termClinical trial

Source: Kaplan et al., Nature Medicine, 2026 (SYNCHRONIZE-MASLD)

How
Injection under the skin
How often
Once a week
How long
48 weeks in the trial (24-week ramp, then 24 weeks at the final dose)

Dose, step by step

  1. Weeks 1–4 0.3 mg
  2. Weeks 5–8 0.6 mg
  3. Weeks 9–12 1.2 mg
  4. Weeks 13–16 2.4 mg
  5. Weeks 17–20 3.6 mg
  6. Weeks 21–24 4.8 mg
  7. Week 25 on 6 mg

Limit. Only dose tested: 6.0 mg once a week. Dose cuts were allowed, but not below 2.4 mg.

  • Only one dose level (6.0 mg) was tested against placebo.

Phase 2 trial

Phase 2 dose-finding trial in adults with overweight or obesity, without diabetes (The Lancet Diabetes & Endocrinology, 2024)

Long-termClinical trial

Source: le Roux et al., The Lancet Diabetes & Endocrinology, 2024

How
Injection under the skin
How often
Once a week, given as two injections on the same day
How long
46 weeks in the trial (a 20-week dose-escalation phase, then 26 weeks of maintenance; this group reached 4.8 mg at week 17)

Dose, step by step

  1. Weeks 1–2 0.3 mg
  2. Weeks 3–4 0.6 mg
  3. Weeks 5–6 0.9 mg
  4. Weeks 7–8 1.2 mg
  5. Weeks 9–10 1.8 mg
  6. Weeks 11–12 2.4 mg
  7. Weeks 13–14 3.3 mg
  8. Weeks 15–16 4.2 mg
  9. Week 17 on 4.8 mg

Limit. Highest dose tested: 4.8 mg once a week.

  • Other groups: 0.6, 2.4 or 3.6 mg, each with its own ramp.
  • From week 11, people with stomach or bowel side effects could adjust the ramp, so some ended on a lower dose than planned.

These doses were tested in clinical trials under medical supervision. They aren’t approved for use, and a research vial is not the product that was tested.

Community protocols. Reported online. Not clinically validated.

Community reports Collection date: 30 Sep 2026

The only grey-market pattern found is adding survodutide to tirzepatide as a home-made substitute for retatrutide. People usually start at 0.2–0.6 mg once a week and step up to about 1–2.4 mg.

More about this

Reports are few, and many posts in the main forum come from clinical-trial participants rather than grey-market users.

Not testedFrequently encountered in reviewed sources

Add-on to tirzepatide (“make your own retatrutide”)

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
Starts at 0.2–0.6 mg (some start at 1 mg); users report working doses of about 1–2.4 mg
How often
Once a week, usually a few days apart from the tirzepatide shot (for example tirzepatide on Friday, survodutide on Sunday)
Route
Injection under the skin
Timing
Mid-way between tirzepatide doses, or in place of one half of a split tirzepatide dose
How long
Open-ended
Ramp
Some follow the trial’s early steps (0.3 mg, then 0.6 mg, then 1.2 mg); others go 0.5 mg to 1.5 mg, or 0.6 mg to 1 mg to 2 mg to 2.4 mg over several weeks
  • Users choose it to add glucagon-receptor action on top of tirzepatide, hoping to break a weight-loss stall without retatrutide’s heart-rate effects.
  • Most keep tirzepatide at 5–15 mg a week while adding survodutide. Some forum members suggest mazdutide instead, as a milder option.
  • Sold as research vials (7.5 mg vials mentioned).
Sources (4)

Not testedFringe

Swap one half of a split tirzepatide week for survodutide

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
Survodutide in place of one 2.5 mg tirzepatide shot
How often
Two shots a week (survodutide Monday, tirzepatide Thursday)
Route
Injection under the skin
  • One user’s plan; included to show how split-dosing habits carry over.
Sources (1)

Where the numbers come from

Starting doses are copied from Boehringer Ingelheim’s trial ramp (users say “as listed in the studies”). The tirzepatide-plus-survodutide idea is a forum invention meant to imitate retatrutide’s three-hormone action.

Research notes

Evidence is thin: one small subreddit (about 450 members), and many of its posts come from people in Boehringer Ingelheim trials, not grey-market users. No clinic, vendor protocol, book, podcast or news report on grey-market survodutide dosing was found. Mazdutide is discussed as an alternative add-on in the same threads.

Measurement basics and calculator

Explore vial arithmetic

What it is. In plain English.

An investigational GLP-1 and glucagon dual agonist with Phase 3 obesity results and ongoing liver-disease research.

A once-weekly injectable peptide developed by Boehringer Ingelheim with Zealand Pharma.

It is designed to activate GLP-1 and glucagon receptors. Appetite, energy use and liver-fat effects are proposed mechanisms under study; they do not establish why an individual loses weight or improves liver disease.

Reviewed 2026-10-01.

Structure. Nothing to show yet.

No experimental 3D structure of survodutide is in the .

Searches by name and by its code, BI 456906, found nothing, and none of the GLP-1 and glucagon receptor entries contains it. PubChem lists it without a sequence.

Checked 30 Sep 2026.

Specs. The facts at a glance.

Type
acylated peptide
Sold as
  • Survodutide 10 mg
Regulatory status
Investigational. Not approved.
Also known as
Boehringer Ingelheim, BI 456906

Sources. What this page rests on.

Every source behind this page, with what it says and when it was checked, is in the Source library.

Survodutide in the Source library

Original overview and research notes · annotated 2026-10-01

Historical collection text. Read alongside the claim corrections above; identity or evidence qualifications may supersede this wording.

Weight loss and fatty liver treatment

A glucagon and GLP-1 dual agonist in late-stage trials for obesity and fatty liver.

A once-weekly injectable peptide developed by Boehringer Ingelheim with Zealand Pharma.

The GLP-1 side reduces appetite. The glucagon side raises energy expenditure and pulls fat out of the liver, which makes it a candidate for MASH, fatty liver disease with inflammation.

In Phase 2, people who stayed on the planned dose lost about 19% of body weight at 46 weeks, and up to 83% of MASH patients improved. Phase 3 SYNCHRONIZE trials are underway.

Original status record: Investigational. Not approved.

More in Weight & metabolism.

Glossary

GLP-1 / GIP

Gut hormones released after eating that raise insulin and reduce appetite. The basis of today’s weight-loss drugs.

Full glossary

Glossary

Phase 1 / 2 / 3

Stages of human drug testing: safety in a few people, then effectiveness in hundreds, then large confirmatory trials in thousands. Most compounds fail along the way.

Full glossary

Glossary

Protein Data Bank (PDB)

The free worldwide archive of 3D structures of proteins and other molecules measured in experiments. Each entry has a four-character code, like 7KI0.

Full glossary